Full-Time

Manufacturing Technician 4 Lead

Updated on 9/16/2026

Resilience

Resilience

1,001-5,000 employees

Cyber insurance paired with risk-quantifying SaaS

Compensation Overview

$26 - $40.50/hr

+ Annual cash bonus + 401(k) company match

No H1B Sponsorship

West Chester Township, OH, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Claude
GMP
SAP Products

Get referred to Resilience

See people who can refer or advise you

Requirements
  • Significant experience in a pharmaceutical, biotechnology, or current Good Manufacturing Practices-regulated manufacturing environment.
  • Advanced knowledge of current Good Manufacturing Practices requirements and quality systems, including deviations, change control, and data integrity.
  • Demonstrated ability to work independently and resourcefully to resolve complex production issues and provide guidance to team members in a fast-paced production environment.
  • Proven ability to review and ensure the accuracy of critical Good Manufacturing Practices documentation and batch records.
  • Demonstrated ability to work with limited supervision and independently determine daily priorities, using strong organizational, analytical, and problem-solving skills to make informed decisions under pressure.
  • Applied quantitative skills sufficient to interpret production data, evaluate trends, and support investigations and continuous improvement work.
  • Experience providing on-the-job training to peers in a manufacturing environment.
  • Ability to effectively read, write, speak, and understand English to communicate technical information cross-functionally.
  • Ability to work effectively as part of a team in a fast-paced production environment.
  • Ability to perform the physical requirements of a primarily non-sedentary role, including climbing, kneeling, repetitive motion, temperature changes, and exerting up to 100 pounds of force to move objects.
  • Ability to pass an eye exam during onboarding.
  • Ability to participate in an occupational health program and use required personal protective equipment.
  • Ability to adhere to the established Quality Management System, Quality Manual, Quality Policy, Standard Operating Procedures, current Good Manufacturing Practices, and other applicable regulations and standards.
Responsibilities
  • Lead and monitor complex process activities to ensure successful operations on the production floor.
  • Perform technician tasks as required, including start-up, equipment operation, manual packaging, and line clearances.
  • Perform inventory control and reconciliation activities using SAP and WES.
  • Execute protocols as required for equipment qualification and process validation work.
  • Ensure work requirements are followed on the production floor in accordance with Standard Operating Procedures and current Good Manufacturing Practices.
  • Support lean activities, including 5S, problem-solving, and serving as a continuous improvement project resource.
  • Perform advanced-level batch record and Good Manufacturing Practices documentation entries on the production floor, including complex or non-routine documentation, and provide guidance to team members on documentation accuracy.
  • Review operational Standard Operating Procedures, forms, and batch records for accuracy; propose revisions and update documents where needed.
  • Maintain all required certifications and qualifications for the assigned work area.
  • Serve as a technical resource for the team, providing subject-matter support to production and mechanical technicians.
  • Act as a certified on-the-job trainer on assigned equipment and process tasks, training and supporting team members.
  • Collaborate with Management and Engineers on packaging floor initiatives.
  • Apply problem-solving and prioritization skills to make independent decisions and provide guidance to team members on daily operational activities.
  • Prepare and lead daily Tier 0 meetings.
Desired Qualifications
  • High school graduate, vocational school graduate, or equivalent.
  • Four or more years of experience in a pharmaceutical, biotechnology, or current Good Manufacturing Practices-regulated manufacturing environment.
  • Prior experience serving as a subject-matter resource or trainer on the production floor.
  • Experience in a lean manufacturing environment.
  • Working knowledge of Microsoft applications, SAP, Veeva Vault, and generative artificial intelligence language tools such as Claude.

Resilience provides cyber insurance to mid-market and large enterprises and licenses the Resilience Solution, a SaaS platform that translates a company’s security posture into a financially oriented action plan used for underwriting and risk management. The platform quantifies technology controls, estimates ROI of security investments, and informs insurance pricing. It runs a risk operations center with continuous threat intelligence and in-house claims handling, emphasizing third-party risk. Goal: move beyond risk transfer by actively improving client security and reducing losses across sectors such as manufacturing, agriculture, and healthcare.

Company Size

1,001-5,000

Company Stage

Growth Equity (Venture Capital)

Total Funding

$3.2B

Headquarters

San Diego, California

Founded

2020

Get referred to Resilience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The July 30, 2026 Lilly deal adds $750 million and 400 Cincinnati jobs.
  • Full KwikPen operations start in early 2027, expanding exposure to obesity and diabetes demand.
  • Oak Hill Advisors funded up to $825 million in 2025, extending liquidity runway.

What critics are saying

  • Resilience's growth depends heavily on Lilly, making 2027 contract renewals existential.
  • The 2025 OHA financing and lease cleanup show a capital-hungry business with underused sites.
  • Moving headquarters from San Diego to Blue Ash cuts 200 jobs and can damage recruiting.

What makes Resilience unique

  • Resilience combines CDMO manufacturing with device assembly, packaging, and cold-storage in one network.
  • Blue Ash, West Chester, and Toronto anchor a regulated North American manufacturing platform.
  • Lilly has trusted Resilience since 2023, producing over 150 million doses.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Tuition Reimbursement

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
BioSpace
Jul 31st, 2026
Lilly and Resilience invest $750M in diabetes and obesity drug device supply.

Lilly and Resilience invest $750M in diabetes and obesity drug device supply. July 31, 2026 | The investment will expand Resilience's U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines. Eli Lilly is expanding its partnership with service provider Resilience, with the pair committing $750 million to U.S. drug manufacturing capacity. The partners are using the cash to bolster Resilience's operations in the Cincinnati region. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. The contract development and manufacturing organization (CDMO) is preparing the site for expansion with the aim of starting full operations early next year. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. May 13, 2026 Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. The addition of the new roles will bring the number of jobs created by Resilience in Ohio - where the CDMO has two sites around Cincinnati - up to 1,400. Resilience also has plants in Philadelphia and Toronto. The spend on the Ohio site continues Resilience's rapid rise. Launched in 2020 with more than $800 million from backers including Arch Venture Partners and 8VC, the CDMO went on to form pacts with companies including AstraZeneca, Sanofi and Takeda while raising almost $2.5 billion across two financing rounds, a debt deal and a loan from the U.S. Department of Defense. Resilience has used the money to add manufacturing capacity. The CDMO expanded a facility in West Chester, Ohio, in 2023; invested $225 million in a Cincinnati plant in 2024; and grew at two Ohio locations in 2025. In June, Resilience moved its corporate headquarters from San Diego to Blue Ash, Ohio, a northern suburb of Cincinnati. The company has partnered with JobsOhio to help staff the sites. The CDMO began working with Lilly in 2023. Resilience's archives lack a press release naming Lilly as a partner in 2023, although that year the CDMO did disclose a 10-year biomanufacturing alliance with an unnamed "leading pharmaceutical company." At the time, Resilience predicted the deal would support record revenues. Resilience has made more than 150 million doses of medicines for Lilly. Eli Lilly's latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization. May 8, 2026

Hospital Management
Jul 31st, 2026
Resilience and Lilly to increase US medicines production with $750m investment.

Resilience and Lilly to increase US medicines production with $750m investment. The investment will support Resilience's advanced manufacturing operations in Cincinnati. Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly's KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US. The investment will support the expansion of Resilience's advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number of jobs generated by Resilience across its Ohio sites will exceed 1,400. Preparation for the site expansion has commenced, and complete operations are projected to begin in early 2027. The expanded collaboration builds upon a strategic partnership between the two firms first formed in 2023. This initiative is in response to growing patient demand for injectable treatments for diabetes and obesity in the US. Resilience president and CEO William Marth said: "Hospital Management is proud of what Hospital Management has built together with Lilly and this new expansion as Hospital Management scale production of complex medicines in Ohio. "Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the US, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Lilly executive vice-president and manufacturing operations president Edgardo Hernandez said: "As demand for our medicines continues to increase, scaling complex manufacturing programmes requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time." The partnership has so far resulted in the production of more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats. Resilience operates two facilities in the region, employing nearly 1,000 staff across various functions. The location in Blue Ash, Ohio, was recently established as Resilience's global headquarters. The company's partnerships with REDI Cincinnati, JobsOhio, and Ohio Life Sciences have also supported workforce development efforts in the Cincinnati area. Prior to this, Eli Lilly and Company entered an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Give your business an edge with its leading industry insights.

TechStartups
Jul 30th, 2026
Venture Capital & Startup Funding Roundup, July 30, 2026: Bessemer Venture Partners, G2 Venture Partners, ICONIQ Growth, Kleiner Perkins, Lightspeed & More - Tech Startups

Tech investors are doubling down on the infrastructure underpinning today’s AI boom – from satellites in orbit to power-hungry data centers on Earth. The day’s largest deals span space tech, clean energy and AI-infused enterprise platforms, signaling where capital is flowing: into hardware-heavy, mission-critical fields. Satcom manufacturer K2 Space ($500M Series D) and thermal-battery startup Antora Energy ($550M

WTWH Media
Jul 30th, 2026
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing.

Resilience, Lilly invest $750M in pharma, KwikPen manufacturing. Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience's advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience's production in that region includes the Lilly KwikPen injectable device for delivering GLP-1 therapies for diabetes and obesity. Adding KwikPen production also creates at least 400 new high-skilled jobs. That brings the total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Resilience and Lilly have preparation underway for the campus expansion, with full operations slated to begin in early 2027. This adds to the partnership that has, to date, produced more than 150 million doses of medicine for patients in the U.S. in vial and pre-filled syringe formats. Together, the companies offer one of the nation's largest sterile injectable manufacturing operations, they said in a news release. Commentary from Resilience and Lilly officials. William S. Marth, president and CEO of Resilience, said: "We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Edgardo Hernandez, Lilly's EVP and president, Manufacturing Operations, said: "As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today's announcement highlights Resilience's role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments."

AMS Group, LLC
Jul 30th, 2026
Lilly, Resilience to invest $750 million in US drug manufacturing expansion.

Lilly, Resilience to invest $750 million in US drug manufacturing expansion. July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supply chain, Resilience said on Thursday. Global drugmakers have been ramping up U.S. manufacturing since last year and stockpiling inventory as President Donald Trump's administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically. - Resilience said the investment will increase the production of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region. - The company's manufacturing operations in the region will now include Lilly's KwikPen injectable device for treating diabetes and obesity, it added. - The multi-year manufacturing partnership between Lilly and Resilience, which began in 2023, has already produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats, according to Resilience. - Lilly's manufacturing head Edgardo Hernandez said the partnership reflects the drugmaker's efforts to meet rising demand for its medicines. - Lilly's U.S. capital expansion commitments since 2020 total more than $55 billion and it plans to break ground on several of its recently announced U.S. manufacturing sites this year. (Reporting by Christy Santhosh in Bengaluru; Editing by Jonathan Ananda)